Pfizer Pipeline Update Includes Resubmission Plans For Osteoporosis Drug Lasofoxifene
This article was originally published in The Pink Sheet Daily
Executive Summary
The pharma giant has 85 new molecular entities in development, with 99 total programs in Phase I through Phase III.